Cargando…
Phase I study of imatinib, cisplatin and 5-fluoruracil or capecitabine in advanced esophageal and gastric adenocarcinoma
BACKGROUND: Despite all benefit provided by established therapies prognosis of gastric cancer remains poor. Targeted inhibition of platelet derived growth factor receptor (PDGFR) by imatinib may influence tumor growth and amplify chemotherapeutic effects. METHODS: This phase I study evaluated dose l...
Autores principales: | Mayr, Martina, Becker, Karen, Schulte, Nadine, Belle, Sebastian, Hofheinz, Ralf, Krause, Annekatrin, Schmid, Roland M, Röcken, Christoph, Ebert, Matthias P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3529191/ https://www.ncbi.nlm.nih.gov/pubmed/23228190 http://dx.doi.org/10.1186/1471-2407-12-587 |
Ejemplares similares
-
Correlation between polymorphism of TYMS gene and toxicity response to treatment with 5-fluoruracil and capecitabine
por: Vitello, Stefano, et al.
Publicado: (2020) -
Comparison of neoadjuvant chemoradiation with carboplatin/ paclitaxel or cisplatin/ 5-fluoruracil in patients with squamous cell carcinoma of the esophagus
por: Münch, Stefan, et al.
Publicado: (2017) -
Comparison of definite chemoradiation therapy with carboplatin/paclitaxel or cisplatin/5-fluoruracil in patients with squamous cell carcinoma of the esophagus
por: Münch, Stefan, et al.
Publicado: (2018) -
Definitive Chemoradiotherapy with Capecitabine and Cisplatin in Patients with Esophageal Cancer: A Pilot Study
por: Lee, Soo Jung, et al.
Publicado: (2009) -
Durable effect of imatinib and metronomic chemotherapy with capecitabine in pancreatic carcinoma
por: Al-Sukhun, Sana, et al.
Publicado: (2023)